Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 5/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | LAP3 | P28838 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL536227 | 1.00 | ALDH1A1 (0.55) | ALDH1A1MAPK1TDP1L3MBTL1SLC6A2 | |
| SCHEMBL2231648 | 1.00 | ALDH1A1 (0.55) | ALDH1A1MAPK1TDP1L3MBTL1SLC6A2 | |
| SCHEMBL10727982 | 0.91 | LMNA (0.57) | ALDH1A1MAPK1TDP1L3MBTL1SLC6A2 | |
| SCHEMBL10727978 | 0.91 | LMNA (0.57) | ALDH1A1MAPK1TDP1L3MBTL1SLC6A2 | |
| SCHEMBL11182822 | 0.88 | L3MBTL1 (0.50) | ALDH1A1MAPK1TDP1L3MBTL1SLC6A2 | |
| SCHEMBL3736834 | 0.85 | ATM (0.65) | ALDH1A1TDP1LTA4HLAP3ATM | |
| SCHEMBL22615678 | 0.85 | ATM (0.65) | ALDH1A1TDP1LTA4HLAP3ATM | |
| SCHEMBL11845149 | 0.84 | L3MBTL1 (0.46) | ALDH1A1MAPK1TDP1L3MBTL1SLC6A2 | |
| SCHEMBL8792364 | 0.84 | PTGS1 (0.52) | ALDH1A1SLC6A2LMNALTA4HLAP3 | |
| Mandelic Acid, Methyl Ester SCHEMBL7704691 | 0.83 | ALDH1A1 (0.50) | ALDH1A1MAPK1TDP1L3MBTL1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102791693-B | Hepatitis c virus inhibitors | BRISTOL-MYERS SQUIBB CO. (US) | 2016-04-13 | — | — | CN | disclosed |
| CN-104072486-B | As the connection-1H-benzoglyoxaline of hepatitis C virus inhibitors | SQUIBB BRISTOL MYERS CO. (US) | 2016-04-06 | — | — | CN | disclosed |
| CN-101998954-B | Conformationally restricted biphenyl derivatives for use as hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2015-06-03 | — | — | CN | disclosed |
| CN-102459250-B | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2015-05-06 | — | — | CN | disclosed |
| CN-102448956-B | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2015-05-06 | — | — | CN | disclosed |
| CN-104447707-A | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2015-03-25 | — | — | CN | disclosed |
| CN-102459281-B | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2015-03-11 | — | — | CN | disclosed |
| CN-101558059-B | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2014-12-03 | — | — | CN | disclosed |
| CN-102378762-B | Hepatitis c virus inhibitors | BRISTOL-MYERS SQUIBB CO. (US) | 2014-10-29 | — | — | CN | disclosed |
| CN-102227407-B | Hepatitis c virus inhibitors | BRISTOL-MYERS SQUIBB CO. (US) | 2014-10-22 | — | — | CN | disclosed |
| CN-102015692-A | Heterocyclic derivatives as hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2011-04-13 | — | — | CN | disclosed |
| CN-102007122-A | Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2011-04-06 | — | — | CN | disclosed |
| CN-101998954-A | Conformationally restricted biphenyl derivatives for use as hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2011-03-30 | — | — | CN | disclosed |
| CN-101998952-A | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2011-03-30 | — | — | CN | disclosed |
| CN-101754966-A | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2010-06-23 | — | — | CN | disclosed |
| CN-101558059-A | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-10-14 | — | — | CN | disclosed |
| US-20080146602-A1 | Thienopyridine Derivatives, Production Method and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-06-19 | — | — | US | disclosed |
| EP-1751167-A1 | THIENOPYRIDINE DERIVATIVES, PRODUCTION METHOD AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005111046-A1 | THIENOPYRIDINE DERIVATIVES, PRODUCTION METHOD AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-24 | — | — | WO | disclosed |
| EP-0554455-A1 | OPTICALLY ACTIVE INTERMEDIATE AND PRODUCTION THEREOF | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1993-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146602-A1 | Thienopyridine Derivatives, Production Method and Use Thereof | IL4, IL5, TSLP | ALDH1A1 1425/4885MAPK1 423/4885TDP1 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.